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Abstract
Background The most commonly performed bariatric pro-
cedures are laparoscopic sleeve gastrectomy (LSG) and
laparoscopic Roux-en-Y gastric bypass (LRYGB). There
are major differences between LSG and LRYGB during
postoperative period. Optimization of the postoperative
care may be achieved by using enhanced recovery after
surgery (ERAS) protocol, which allows earlier functional
recovery.
Purpose The aim was to assess differences in the course of
postoperative care conducted in accordance with ERAS pro-
tocol among patients after LSG and LRYGB.
Material and Methods Data concerning patients treated for
morbid obesity were prospectively gathered in one academic
center. Patients were divided into two groups: LSG (n = 364,
63.41%) and LRYGB (n = 210, 36.59%). Multiple factors
were used as endpoints to determine the influence of the type
of bariatric procedure on postoperative course.
Results The rate of postoperative nausea and vomiting and
incidence of intravenous fluid administration during the oper-
ation was higher in LSG group. LRYGB patients were able to
tolerate higher oral fluid intake volumes during the first and
the second postoperative day. Mean diuresis during the second
and the third postoperative day was significantly higher in
LRYGB group. Administration of diuretics and painkillers
was comparable between groups, while the risk of fever after
the operation was higher in LRYGB group. Mean length of stay
was higher in LSG group (LRYGB vs. LSG, 3.46 days ± 1.58
vs. 3.64 days ± 4.41, p = 0.039).
Conclusions In our opinion, postoperative treatment after
LSG requires more supervision and longer time until function-
al recovery is achieved.
Keywords Bariatric surgery . Sleeve gastrectomy . Gastric
bypass . Postoperative care . ERAS
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Introduction
Bariatric surgery seems to be the most effective treatment for
obesity and obesity-related metabolic comorbidities [1]. The
most commonly performed bariatric procedures worldwide
are laparoscopic sleeve gastrectomy (LSG) and laparoscopic
Roux-en-Y gastric bypass (LRYGB) [2, 3]. Enhanced recov-
ery after surgery (ERAS) protocol during the course of post-
operative care includes avoiding use of catheters and intra-
abdominal drains, prophylactic use of antithrombotic medica-
tions, early mobilization, early enteral feeding, and multimod-
al postoperative analgesia [4, 5]. Perioperative care carried out
in accordance to ERAS protocol seems to be a safe and feasi-
ble method for both operations, which allows to reduce length
of hospital stay and readmission rates without influencing
morbidity [6, 7]. Contrary to popular opinion, the main benefit
from implementing the protocol is not the ability to discharge
the patient as early as it is possible, but as soon as they reach
full functional recovery. High demand for bariatric operations
creates tendency to perform them as outpatient procedures.
Optimization of the postoperative period according to ERAS
protocol is a key factor for this approach [8, 9]. Major differ-
ences between patients after LSG and LRYGB during postop-
erative course are not well known. Achieving early recovery
of gastrointestinal function seems to be significant factor con-
tributing to decreasing discomfort or risk of prolonged hospi-
tal stay after abdominal surgery [10]. Although there are plen-
ty of studies comparing early and late postoperative outcomes
of those two procedures, none so far focused on postoperative
care, especially with ERAS approach.
Purpose
The aim was to assess the differences in postoperative course
among patients treated according to ERAS protocol submitted
to LSG and LRYGB.
Material and Methods
Study Design
Data concerning bariatric patients treated for morbid obe-
sity in one academic center were prospectively gathered.
Recommendations of the Metabolic and Bariatric Surgery
Section of the Polish Surgical Society were used as indi-
cation for surgery, that is body mass index (BMI) ≥ 35 kg/
m2 with obesity-related comorbidities or BMI ≥ 40 kg/m2
[11, 12]. Inclusion criteria for this study were informed
consent to participate in the study, meeting the eligibility
criteria for bariatric treatment, either for LSG or LRYGB.
We excluded patients with insufficient data (Fig. 1). Study
was designed and described according to all STROBE
checklist points for observational studies [13].
Data collection was performed by authors, who were
also directly involved in treatment process. Database in-
cluded demographic characteristics and factors related to
the surgery. Features describing patient profile included
age, sex, maximal preoperative BMI, BMI on a day of
operation, American Society of Anesthesiologists (ASA)
class, and main comorbidities (cardiovascular diseases, ar-
terial hypertension, obstructive sleep apnea syndrome, di-
abetes mellitus type 2). Perioperative variables were type
of procedure, operative time, intraoperative adverse events,
postoperative complications, length of hospital stay (LOS),
readmissions, reoperations, fever, postoperative nausea
and vomiting, stool passage after surgery during the hos-
pitalization, diuretics management, painkillers manage-
ment, and data concerning postoperative fluid management
(intravenous fluid administration, oral fluid intake, and di-
uresis) during the operation day and first three consecutive
postoperative days. Patients were divided into two groups:
LSG and LRYGB. An intraoperative adverse event was
defined as any iatrogenic harmful event occurring during
operation, which had not derived from standard LSG or
LRYGB technique. We defined postoperative complica-
tions as adverse events occurring within 1 year of the pro-
cedure. Rhabdomyolysis was defined as elevated levels of
creatinine phosphokinase (CPK > 1000 IU/l) with
coexisting increase of myoglobin level. Gastrointestinal
leakage was defined as leakage from the GI tract clinically
diagnosed and confirmed with radiological examination.
Postoperative hemorrhage was defined as a significant
drop in hemoglobin count with either clinically demon-
strated hemorrhage requiring reoperation or need of eryth-
rocyte transfusion. LOS was defined as period from admis-
sion to discharge, based on number of nights spent in hos-
pital. All patients were admitted to hospital 1 day prior to
surgery, so if the patient would be discharged on the day of
surgery, his LOS would be 1 day.
Treatment Protocol
In order to minimize bias, patients were treated in accordance
with enhanced recovery after surgery (ERAS) pathway, in-
cluding preoperative, intraoperative, and postoperative inter-
ventions [6, 14, 15]. During the preoperative period, patients
were appropriately counseled. The health status of all patients
was assessed with particular emphasis on incidence of type 2
diabetes mellitus, hypertension, obstructive sleep apnea, and
gastroesophageal reflux disease (GERD). Incidence of GERD
was assessed during history taking by a direct question and
questions concerning taking proton-pump inhibitors.
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Preoperative consultations included also routine endoscopy
of the upper gastrointestinal tract with assessment of hiatal
hernia and esophageal, gastric, or duodenal mucosa patholo-
gy. In case of a large hiatal hernia with inflammatory lesions
in esophageal mucosa, patients were treated with
pantoprazole and qualified for LRYGB. If hiatal hernia did
not coexist with inflammatory lesions in esophageal mucosa
or clinical symptoms of GERD requiring pharmacotherapy,
we suggested LSG with possible simultaneous cruroplasty in
case of large gap in the diaphragm. Final decision was made
by patients. During endoscopy, gastric mucosa tissue biopsy
sample was obtained to perform rapid urease test for
Helicobacter pylori infection (Campylobacter-like organism
(CLO) test). In case of positive result of CLO test, eradication
was conducted accordingly to guidelines from the Polish
Society of Gastroenterology for the diagnosis and treatment
of Helicobacter pylori infection [16]. Nutritional intervention
included high-protein and high-carbohydrate drinks. General
anesthesia, obligatory in laparoscopic surgery, was conducted
accordingly to the optimized bariatric anesthetic protocol
with the use of multimodal analgesics. Patients undergoing
LRYGB and LSG did not require standard usage of the na-
sogastric tubes and intra-abdominal drains. Postoperative
pain management did not include standard usage of opioids.
Enoxaparin used for antithrombotic prophylaxis was admin-
istered for 14 consecutive postoperative days. All patients
received routinely pantoprazole (40 mg/day) for 30 consecu-
tive postoperative days or longer in case of postoperative
incidence of GERD symptoms. After surgery, patients were
mobilized and had enteral feeding introduced early. Our tar-
get is to not use intravenous fluids in postoperative period
routinely. Fluids were given only if we observed absence of
sufficient functional recovery: vomiting, insufficient oral flu-
id intake (less than 500 ml until 4:00 pm), insufficient diure-
sis, or biochemical symptoms of rhabdomyolysis expressed
by the high blood level of myoglobin, CPK, and low GFR
(glomerular filtration rate). Every bariatric patient in our cen-
ter is scheduled to have three follow-up appointments:
2 weeks after discharge, 1 month after discharge, and
3 months after discharge.
Surgical Technique
Surgical techniques for LSG and LRYGB were standardized
[17]. Veress needle was used to achieve pneumoperitoneum
(15 mmHg). Routine procedure required insertion of four tro-
cars during LSG and five trocars during LRYGB. A sealer/
divider or ultrasonic shears were used for a dissection and
coagulation (LigaSure Atlas™, Covidien or SonoSurg™,
Olympus). A 34-French gastric bougie inserted into the stom-
ach along the lesser curvature was used to calibrate the gastric
sleeve. Gastrectomy started 4–5 cm proximal to the pylorus
with continuously applied linear staplers, starting with two
firings of 60 mm, Ethicon Echelon EndoFlex with gold car-
tridges (3.8 mm open stapler height, 1.8 mm closed stapler
height), then continued with blue cartridges (3.6 mm open
stapler height, 1.5 mm closed stapler height) straight to the
angle of His. Stapler line was reinforced by a running 3-0 PDS
suture. Resected portion of the stomach was removed from the
peritoneal cavity through the left flank trocar site during LSG.
LRYGB required creation of a pouch by one horizontal 45-
mm stapler followed by vertical stapling toward the angle of
His, until the pouch was totally separated from the rest of the
stomach. Gastrojejunal anastomosis was created with a linear
stapler Ethicon Echelon EndoFlex (45 mm, with blue car-
tridges, open staple height 3.5 mm, closed staple height
1.5 mm) with hand-sewn closure of the remaining defect
(3/0 Vicryl, Ethicon). The length of alimentary and enzymatic
limb was standardized in all patients, respectively, 150 and
100 cm. Jejunojejunal anastomosis was created using a linear
stapler Ethicon Echelon EndoFlex (45 mm, with white car-
tridge, open staple height 2.5 mm, closed staple height 1 mm).
Assessed for eligibility (n=580)
Excluded (n=6)
Lack of necessary data (n=6)
Analysed (n=364)
Allocated to LSG group (n=364) Allocated to LRYGB group (n=210)
Analysed (n=210)
Allocation
Analysis
Included (n=574)
EnrollmentFig. 1 Study flowchart
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Petersen’s defect was not routinely closed as prevention for
internal hernias. A routine 10/12 mm port sites closure was
performed to prevent herniation.
Analysis of Endpoints
Our primary endpoints were factors determining the influence
of the type of bariatric procedure on postoperative functional
recovery:
– Postoperative nausea and vomiting (PONV)
– Stool passage
– Intravenous fluid administration
– Oral fluid intake during hospitalization
– Diuresis during hospitalization
– Diuretics management
– Extra painkillers management
– Postoperative fever
– Length of hospitalization (LOS)
– Readmissions
Secondary endpoint was analysis of operative outcomes
influenced by the type of bariatric procedure:
– Operative time
– Mean IV fluid administration during the operation
– Intraoperative adverse events
– Postoperative complications
– Reoperations
Statistical Analysis
All data were analyzed with Statistica version 12.0 PL
(StatSoft Inc., Tulsa, OK, USA). The results are presented as
mean standard deviation (SD), median and interquartile range
(IQR), and odds ratio (OR) with 95% confidence intervals
(CI) when appropriate. The study of categorical variables used
the chi-square test of independence. Shapiro-Wilk test was
used to check for normal distribution of data, and the
Student t test was used for normally distributed quantitative
data. For non-normally distributed quantitative variables, the
Mann-Whitney U test was used. Influence of the type of bar-
iatric procedure on postoperative complications, gastrointesti-
nal leakage, gastrointestinal stricture, postoperative hemor-
rhage, wound infection, pneumonia, reoperation, readmission,
fever, PONV, stool passage, extra pain killer management,
diuretics management, and incidence of intravenous fluid ad-
ministration during the operation day and first to third postop-
erative day rates was analyzed in univariate logistic regression
models. p value < 0.05 was considered statistically significant.
Statistical power analysis was performed with power and sam-
ple size calculator for odds ratio: equality available from:
http://powerandsamplesize.com/Calculators based on method
by Chow et al. [18].
Five hundred eighty patients were treated for morbid
obesity at tertiary referral academic institution from April
2009 to November 2016. Five hundred seventy-four pa-
tients met inclusion criteria and underwent LSG or
LRYGB (362 f ema l e s , 2 1 2 ma l e s , me a n ag e
42.77 ± 11 years). Three hundred sixty-four (63.41%) pa-
tients underwent LSG (245 females, 119 males, mean age
40.88 ± 11.1 years) and 210 (36.59%) patients underwent
LRYGB ( 11 7 f em a l e s , 9 3 m a l e s , m e a n a g e
46.06 ± 10.08 years) (Fig. 1). Median maximal preopera-
tive BMI and BMI on a day of operation were significantly
higher in LRYGB group. Higher ASA classes were more
often present in LRYGB group. Patients in LRYGB group
presented significantly greater rates of comorbidities, in-
cluding cardiovascular diseases (CVD), arterial hyperten-
sion (HTN), and diabetes mellitus (DM). Rates of obstruc-
tive sleep apnea (RD) were similar in bath groups
(Table 1).
Results
Our study group reveals higher risk of PONV in LSG group
(LRYGB vs. LSG, OR 0.16, CI 0.05–0.54, p = 0.003). Amount
of intravenous fluid administration during the operation day
was significantly higher in LSG group (LRYGB vs. LSG,
OR 0.60, CI 0.41–0.89, p = 0.01). Volume of intravenous fluid
administration was comparable in both groups during the first,
second, and third postoperative day. There was no significant
difference in oral fluid intake during the operation day. Oral
f lu id in take dur ing the f i rs t (LRYGB vs. LSG,
1532.94 ml ± 575.4 vs. 1213.62 ml ± 689.46, p < 0.001) and
the second (LRYGB vs. LSG, 1978.23 ml ± 776.86 vs.
1456.77 ml ± 743.38, p < 0.001) postoperative day was signif-
icantly higher among patients who underwent LRYGB.
However, there was no difference in oral fluid intake during
the third postoperative day. Although mean diuresis during the
operation day and first postoperative day was similar in both
groups, mean diuresis during the second (LRYGB vs. LSG,
2683.88 ml ± 916.06 vs. 2369.26 ml ± 767.15, p = 0.001)
and the third (LRYGB vs. LSG, 2662.03 ml ± 798.28 vs.
2346.71 ml ± 848.58, p = 0.034) postoperative day was signif-
icantly higher in LRYGBgroup. The risk of postoperative fever
was higher in LRYGB group (LRYGB vs. LSG, OR 1.93, CI
1.22–3.05, p = 0.005). Administration of diuretics (LRYGB vs.
LSG, OR 1.25, CI 0.89–1.77, p = 0.198) and painkillers
(LRYGB vs. LSG, OR 1.03, CI 0.72–1.47, p = 0.880) was
comparable in both groups. Rates of stool passage during hos-
pitalization were similar in both groups (LRYGB vs. LSG, OR
1.34, CI 0.95–1.88, p = 0,094). Mean LOS was significantly
higher in LSG group (LRYGB vs. LSG, 3.46 days ± 1.58 vs.
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3.64 days ± 4.41, p = 0.039). Readmission rates were not in-
fluenced by the operation (LRYGB vs. LSG, OR 1.70, CI
0.87–3.32, p = 0.119) (Tables 2 and 3).
Operative time was significantly longer in LRYGB group
[LSG vs. LRYGB, 100 (80–120) vs. 140 (110–180),
p < 0.001]. Mean volume of intraoperative fluids
Table 1 Patients and groups baseline characteristics
Parameter All patients LSG LRYGB p
n 574 (100%) 364 (63.41%) 210 (36.59%) –
Females, n (%) 362 (63.07%) 245 (67.31%) 117 (55.71%) 0.005
Males, n (%) 212 (36.93%) 119 (32.69%) 93 (44.29%)
Mean age (years ± SD) 42.77 ± 11 40.88 ± 11.1 46.06 ± 10.08 < 0.001
Median maximal preoperative BMI, kg/m2 (IQR) 46.87 (42.93–51.63) 46.04 (42.81–50.61) 48.26 (43.42–53.71) 0.009
Median BMI on a day of operation, kg/m2 (IQR) 45.28 (41.45–50.03) 44.86 (41.31–48.9) 46.06 (41.81–51.64) 0.049
Preoperative BMI loss, kg/m2 (IQR) 0.99 (0–2.47) 0.78 (0–2.26) 1.38 (0–2.81) 0.028
Median ASA (IQR) 2.00 (2.00–3.00) 2.00 (2.00–2.00) 2.00 (2.00–3.00) < 0.001
ASA class, n (%) 1 15 (2.61%) 14 (3.85%) 1 (0.48%) < 0.001
2 386 (67.25%) 262 (71.98%) 124 59.05(%)
3 157 (27.35%) 84 (23.08%) 73 (34.76%)
Cardiovascular diseases, n (%) 107 (18.64%) 53 (14.56%) 54 (25.71%) < 0.001
Hypertension, n (%) 395 (68.82%) 229 (62.91%) 166 (79.05%) < 0.001
Diabetes mellitus, n (%) 198 (34.49%) 88 (24.18%) 110 (52.38%) < 0.001
Obstructive sleep apnoea, n (%) 45 (7.84%) 29 (7.97%) 16 (7.62%) 0.881
Table 2 Postoperative course and functional recovery in groups LSG vs. LRYGB
Total LSG LRYGB p
n 574 (100%) 364 (63.41%) 210 (36.59%) –
PONV 33 (5.75%) 30 (8.24%) 3 (1.43%) < 0.001
Stool passage 277 (48.26%) 166 (45.6%) 111 (52.86%) 0.119
Mean IV fluid administration during the operation day (ml ± SD) 807.08 ± 439.53 801.96 ± 404.61 819.79 ± 520.85 0.811
Mean IV fluid administration during the first post-op day (ml ± SD) 1715.58 ± 1031.19 1632.05 ± 906.08 1846.94 ± 1194.08 0.287
Mean IV fluid administration during the second post-op day (ml ± SD) 1537.03 ± 885.84 1499.12 ± 899.76 1600.58 ± 864.84 0.276
Mean IV fluid administration during the third post-op day (ml ± SD) 1473.38 ± 720.0–0 1592.56 ± 645.94 1328.12 ± 787.24 0.125
IV fluid administration during the operation day 171 (29.79%) 122 (33.52%) 49 (23.33%) 0.003
IV fluid administration during the first post-op day 319 (55.57%) 195 (53.57%) 124 (59.05%) 0.340
IV fluid administration during the second post-op day 182 (31.71%) 114 (31.32%) 68 (32.38%) 0.926
IV fluid administration during the third post-op day 71 (12.37%) 39 (10.71%) 32 (15.24%) 0.518
Mean oral fluid intake during the operation day (ml ± SD) 427.05 ± 432.1 428.55 ± 418.55 424.56 ± 454.96 0.921
Mean oral fluid intake during the first post-op day (ml ± SD) 1333.46 ± 666.58 1213.62 ± 689.46 1532.94 ± 575.4 < 0.001
Mean oral fluid intake during the second post-op day (ml ± SD) 1676.7 ± 799.15 1456.77 ± 743.38 1978.23 ± 776.86 < 0.001
Mean oral fluid intake during the third post-op day (ml ± SD) 1781.68 ± 683.55 1763.15 ± 751.90 1807.27 ± 581.77 0.717
Mean diuresis during the operation day (ml ± SD) 2269.82 ± 814.85 2253.61 ± 768.47 2296.57 ± 887.71 0.573
Mean diuresis during the first post-op day (ml ± SD) 2516.42 ± 802.29 2497.46 ± 781.06 2548.02 ± 837.79 0.508
Mean diuresis during the second post-op day (ml ± SD) 2497.87 ± 844.1 2369.26 ± 767.15 2683.88 ± 916.06 0.001
Mean diuresis during the third post-op day (ml ± SD) 2477.69 ± 839.53 2346.71 ± 848.58 2662.03 ± 798.28 0.034
Diuretic management 327 (56.97%) 200 (54.95%) 127 (60.48%) 0.281
Extra painkiller management 200 (34.84%) 126 (34.62%) 74 (35.24%) 0.949
Postoperative fever 88 (15.33%) 44 (12.09%) 44 (20.95%) 0.006
Median LOS (days, IQR) 3 (2–4) 3 (2–4) 3 (2–4) 0.039
Mean LOS (days ± SD) 3.57 ± 3.6 3.64 ± 4.41 3.46 ± 1.58
Readmissions 37 (6.45%) 19 (5.22%) 18 (8.57%) 0.163
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administration was significantly higher in LRYGB group
(LRYGB v s . LSG , 1 5 5 2 . 4 7 m l ± 537 . 2 4 v s .
1336.05 ml ± 501.87, p < 0.001). Incidence of intraoperative
adverse events was comparable in both groups. Rates of gen-
eral postoperative complications and specific complications,
including gastrointestinal leakage, gastrointestinal stricture,
postoperative, wound infection, and pneumonia, were not
linked the type of bariatric procedure performed. There were
no significant differences in severity of postoperative compli-
cations, assessed in accordance with Clavien-Dindo classifi-
cation, between LSG and LRYGB groups [19]. We did not
observe any significant relation between the type of procedure
and increased risk of reoperation (Tables 4 and 5).
Discussion
Surgery-induced weight loss seems to be highly effective in
treatment of obesity and obesity-related comorbidities [20],
and LRYGB and LSG are currently the most frequently cho-
sen bariatric procedures [21]. In our study, rates of intraoper-
ative adverse events were comparable between groups. The
median operating time was notably longer in LRYGB group,
which might be related to higher volume of intraoperative
fluids. Moreover, these results seem to be consistent with pre-
viously published studies [22–27]. This may have resulted in a
large difference in incidence of necessity to administrate IV
fluids postoperatively on the day of operation. Our data set
revealed also a 5.48% higher rate of IV fluid administration on
the first postoperative day in LRYGB group, but the differ-
ence was not statistically significant. Analysis of postopera-
tive complication rates between LRYGB and LSG, according
to our results and randomized clinical trial by Peterli et al., did
not reveal significant differences [23]. Patients achieve similar
bariatric effect both in terms of weight loss and remission of
obesity-associated comorbidities, regardless of the approach
[28]. Nevertheless, there are major technical differences be-
tween those two operations, and we assume that it may result
Table 3 Influence of LRYGB vs.
LSG group on OR of primary
endpoints
Event OR 95% CI p Test power, %
PONV 0.16 0.05–0.54 0.003 96.36%
Stool passage 1.34 0.95–1.88 0.094 55.95%
IV fluid administration during the operation day 0.60 0.41–0.89 0.010 89.65%
IV fluid administration during the first post-op day 1.41 0.99–2.01 0.054 36.06%
IV fluid administration during the second post-op day 1.05 0.73–1.51 0.792 6.3%
IV fluid administration during the third post-op day 1.5 0.9–2.47 0.115 51.23%
Diuretic management 1.25 0.89–1.77 0.198 36.82%
Extra painkiller management 1.03 0.72–1.47 0.880 5.44%
Fever 1.93 1.22–3.05 0.005 94.22%
Readmissions 1.70 0.87–3.32 0.119 5.15%
Table 4 Early postoperative
outcomes in groups LSG vs.
LRYGB
Total LSG LRYGB p
n 574 (100%) 364 (63.41%) 210 (36.59%) –
Mean operative time (min ± SD) 121.07 ± 47.86 105.99 ± 39.95 146.23 ± 49.45 < 0.001
Median operative time (min, IQR) 115 (87.5–150) 100 (80–120) 140 (110–180)
Mean IV fluid administration
during the operation (ml ± SD)
1416.56 ± 525.32 1336.05 ± 501.87 1552.47 ± 537.24 < 0.001
Intraoperative adverse events 24 (4.18%) 12 (3.3%) 12 (5.71%) 0.163
Postoperative complications 44 (7.67%) 26 (7.14%) 18 (8.57%) 0.542
Clavien-Dindo I–II 27 (4.7%) 18 (4.95%) 9 (4.29%) 0.719
Clavien-Dindo III–V 17 (2.96%) 8 (2.2%) 9 (4.29%) 0.155
Biochemical rhabdomyolysis 10 (1.74%) 3 (0.82%) 7 (3.33%) 0.916
Gastrointestinal leakage 6 (1.05%) 4 (1.1%) 2 (0.95%) 0.868
Gastrointestinal stricture 9 (1.57%) 7 (1.92%) 2 (0.95%) 0.367
Postoperative hemorrhage 7 (1.22%) 3 (0.82%) 4 (1.9%) 0.256
Wound infection 2 (0.35%) 1 (0.27%) 1 (0.48%) 0.759
Pneumonia 6 (1.05%) 2 (0.55%) 4 (1.9%) 0.124
Reoperations 9 (1.57%) 5 (1.37%) 4 (1.9%) 0.317
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in inequalities during the postoperative course and functional
recovery.
Perioperative care according to the principles of ERAS
protocol, which is also applied in our center, was proved to
be feasible, effective, and enabling early discharge in bariatric
surgery [14, 29, 30]. Barreca and colleagues published an
article stating that implementation of ERAS protocol among
bariatric patients led to > 40% of patients being discharged
within 24 h from the operation [31]. The criteria for discharge
defined in ERAS protocol include full mobilization, oral in-
gestion of an appropriate amount of liquid nutrition without
the need for intravenous administration, appropriate diuresis,
adequate post-discharge support (e.g., a family member), and
the lack of objective contraindications for discharge [14]. All
those parameters affect the time to reach functional recovery
which in our opinion is a priority over shorter LOS.
Implementation of ERAS protocol allows earlier functional
recovery and reduction of the profound stress response after
surgery [32].
Most of previous publications comparing LRYGB and
LSG focused on bariatric effect of the operations and resolu-
tion of obesity-related comorbidities. Our study is the first one
that compares early postoperative course and functional re-
covery of the patients undergoing LSG and LRYGB under
ERAS protocol. For patients undergoing surgery in this ap-
proach, first days after the surgery are crucial for maintaining
homeostasis via controlling metabolism, administration of
fluids, and the support of the return of key functions (i.e.,
improvements in cardiopulmonary function, earlier return of
bowel function, earlier resumption of normal activities) [32,
33]. Primary goal is to achieve early functional recovery (lack
of nausea, vomiting, or fever), which is not necessarily asso-
ciated with shorter LOS. Thus, our primary endpoints focused
on these parameters.
PONV is a frequent symptom of delayed functional recov-
ery. Nausea, vomiting, and dehydration are responsible for
17.5% of indications for emergency department returns,
readmissions, and reoperations after bariatric surgery [34].
Post-bariatric nausea and vomiting are directly correlated with
the length of the surgery; they also appear more often in fe-
male patients, non-smokers, and those with prior history of
vomiting or motion sickness [35]. Our results reveal higher
rate of PONVafter LSG. Fluid management of patients in our
study group was comparable, although it slightly favored
LRYGB group. Patients who underwent LRYGB less fre-
quently required intravenous fluid administration during the
operation day and more often preserved high oral fluid intake
during the hospitalization. LRYGB group also achieved
higher urination volume in postoperative course. One of the
factors that determine the decision to discharge a patient after
surgery, according to the ERAS protocol, is a requirement
concerning administration of medications. Diuretic and pain-
killer administration was not influenced by the type of bariat-
ric procedure. Prevalence of postoperative fever after LRYGB
was significantly higher than after LSG in our study group.
Postoperative fever is one of the most consistent signs for
leakage after bariatric surgery, although we did not observe
those relations in a study group [36, 37].
Mean LOS was slightly higher among patients in LSG
group, in opposition to several previous publications, which
included patients who were undergoing non-ERAS periopera-
tive care [26, 27]. Studies by Young et al. and Albeladi et al.
show no significant differences in LOS between LSG and
LRYGB patients [22, 24]. We believe that prolonged LOS
among patients undergoing ERAS protocol after LSG is a re-
sult of higher incidence of PONV and lower oral fluid intake,
which are both associated with worse functional recovery.
Readmission may be more likely to occur within the first
few weeks after surgery for LSG patients compared to
LRYGB patients; nevertheless, LRYGB should be followed
closely within the first 3 months to manage potential compli-
cations that would require readmission [38]. There was no
statistically significant difference in incidence of readmissions
among our patients.
Limitations of the Study
The limitations of the present study are typical for non-
randomized design and relatively small group. Influence of
the type of procedure on excess weight loss and improvement
of obesity-related comorbidities after bariatric treatment was
not analyzed.
Conclusion
There are significant differences in the course of postoperative
care conducted accordingly with ERAS protocol among pa-
tients treated with LRYGB and LSG. Postoperative treatment
Table 5 Influence of LRYGB vs. LSG group on OR of secondary
endpoints
Event OR 95% CI p Test power, %
Intraoperative adverse events 1.78 0.78–4.03 0.169 40.88%
Postoperative complications 1.22 0.65–2.28 0.536 12.25%
Clavien-Dindo I–II 0.86 0.38–1.95 0.720 7.41%
Clavien-Dindo III–V 1.99 0.76–5.25 0.163 42.04%
Biochemical rhabdomyolysis 4.15 1.06–16.22 0.040 73.11%
Gastrointestinal leakage 0.87 1.57–4.77 0.868 5.56%
Gastrointestinal stricture 0.49 0.10–2.38 0.377 20.01%
Postoperative hemorrhage 2.34 0.52–10.54 0.270 28.55%
Wound infection 1.74 0.11–27.92 0.697 8.09%
Pneumonia 3.51 0.64–19.35 0.149 28.55%
Reoperations 1.39 0.37–5.25 0.623 9.52%
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